Xopenex HFA (Levalbuterol Tartrate) - Summary

XOPENEX HFA SUMMARY

XOPENEX HFA (levalbuterol tartrate) Inhalation Aerosol

The active component of XOPENEX HFA (levalbuterol tartrate) Inhalation Aerosol is levalbuterol tartrate, the (R)-enantiomer of albuterol. Levalbuterol tartrate is a relatively selective beta₂-adrenergic receptor agonist (see CLINICAL PHARMACOLOGY).

XOPENEX HFA (levalbuterol tartrate) Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.

See all Xopenex HFA indications & dosage >>

XOPENEX HFA NEWS HIGHLIGHTS

Published Studies Related to Xopenex HFA (Levalbuterol)

A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. [2008.09]

Chronic inhalation of nebulized levalbuterol does not increase mucociliary clearance in healthy subjects. [2008]

Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. [2008]

Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. [2007.12]

An evaluation of levalbuterol HFA in the prevention of exercise-induced bronchospasm. [2007.11]

more >>

Clinical Trials Related to Xopenex HFA (Levalbuterol)

Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma [Completed]

Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD) [Completed]

Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients [Active, not recruiting]

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma [Completed]

Continuous Levalbuterol for Treatment of Status Asthmaticus in Children [Completed]

more >>